

Posttranslational Acylations of the Rat Brain Transketolase Discriminate the Enzyme Responses to Inhibitors of ThDP-Dependent Enzymes or Thiamine Transport

[Vasily A. Aleshin](#) , Thilo Kaehne , [Maria V. Maslova](#) , [Anastasia V. Graf](#) , [Victoria I. Bunik](#) *

Posted Date: 10 November 2023

doi: 10.20944/preprints202310.1571.v2

Keywords: Transketolase; malonylation; acetylation; sirtuin 5; oxythiamine; metformin; amprolium; thiamine; posttranslational modifications



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Posttranslational Acylations of the Rat Brain Transketolase Discriminate the Enzyme Responses to Inhibitors of ThDP-Dependent Enzymes or Thiamine Transport

Vasily A. Aleshin ^{1,2}, Thilo Kaehne ³, Maria V. Maslova ⁴, Anastasia V. Graf ^{1,4} and Victoria I. Bunik ^{1,2,5,*}

¹ Belozersky Institute of Physicochemical Biology, Lomonosov Moscow State University, 119234 Moscow, Russia; aleshin_vasily@mail.ru (V.A.A.); nastjushka@gmail.com (A.V.G.); soloveva_o@list.ru (O.N.S.); bunik@belozersky.msu.ru (V.I.B.)

² Department of Biochemistry, Sechenov University, 119048 Moscow, Russia

³ Institute of Experimental Internal Medicine, Otto von Guericke University, 39106 Magdeburg, Germany; kaehne@med.ovgu.de

⁴ Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia; maslova_masha@mail.ru (M.V.M.)

⁵ Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119234 Moscow, Russia

* Correspondence: bunik@belozersky.msu.ru, +7-495-9394484 (V.I.B.);

Abstract: Transketolase (TKT) is an essential thiamine diphosphate (ThDP)-dependent enzyme of the non-oxidative branch of pentose phosphate pathway, with the glucose-6P flux through the pathway regulated in various medically important conditions. Here, we characterize the brain TKT regulation by acylation in rats with perturbed thiamine-dependent metabolism, known to occur in neurodegenerative diseases. The perturbations are modelled by administration of oxythiamine inhibiting ThDP-dependent enzymes in vivo, or by reduced thiamine availability in the presence of metformin and amprolium, inhibiting intracellular thiamine transporters. Compared to control rats, chronic administration of oxythiamine does not significantly change the modification level of the two detected TKT acetylation sites (K6 and K102), but doubles malonylation of TKT K499, concomitantly decreasing 1.7-fold the level of demalonylase sirtuin 5. The inhibitors of thiamine transporters do not change average levels of TKT acylation or sirtuin 5. TKT structures indicate that the acylated residues are distant from the active sites. The acylations-perturbed electrostatic interactions may be involved in conformational shifts and/or formation of TKT complexes with other proteins or nucleic acids. Acetylation of K102 may affect the active site entrance/exit and subunit interactions. Correlation analysis reveals that the action of oxythiamine is characterized by significant negative correlations of K499 malonylation or K6 acetylation with TKT activity, not observed upon the action of the inhibitors of thiamine transport. However, the transport inhibitors induce significant negative correlations between the TKT activity and K102 acetylation or TKT expression, absent in the oxythiamine group. Thus, perturbations in the ThDP-dependent catalysis or thiamine transport manifest in the insult-specific patterns of the brain TKT malonylation and acetylations.

Keywords: transketolase; malonylation; acetylation; sirtuin 5; oxythiamine; metformin; amprolium; thiamine; posttranslational modifications.

1. Introduction

TKT is a thiamine diphosphate (ThDP)-dependent enzyme of the non-oxidative branch of pentose phosphate pathway (PPP), where ribose-5-phosphate for cellular nucleotide biosynthesis is generated in the oxidative and non-oxidative branches. TKT is a homodimer, with both subunits (each of app. 70 kDa) contributing the amino acid residues for each of the two active sites [1]. TKT regulation by post-translational modifications is suggested by the long-known existence of multiple forms of TKT, which are not due to genetic or splicing factors, but differ in the enzyme charge and

affinity to ThDP [2-4]. The electrostatics-affecting modifications of metabolic enzymes by acylations of their lysine residues, such as the long-known acetylation of histones, are suggested by recent discovery of an interplay between TKT and a NAD⁺-dependent deacylase of negatively charged acyls, sirtuin 5. For example, in adipose-derived mesenchymal stem cells, the sirtuin 5 knockout significantly up-regulates TKT expression [5]. In colorectal cancer cells, blocking the sirtuin 5 expression does not affect the expression of TKT, but decreases the TKT activity, accompanied by impaired availability of ribose-5P for nucleotide synthesis and alleviated by overexpression of TKT in the sirtuin-5-silenced cells [6]. Contrary, overexpression of sirtuin 5, but not its catalytically inactive mutant, increases the cellular TKT activity in the colorectal cancer cells [6]. Overall, the data on the cancer cells presented in this work indicate that malonylation of TKT inactivates the enzyme, that causes DNA damage due to insufficiency of ribose-5P. Yet in the liver of the sirtuin 5 knockout mice, despite the observed increase in malonylation of TKT, the primary effect of the knockout is inhibition of glycolysis, caused by increased malonylation of glyceraldehyde 3-phosphate dehydrogenase [7]. The accumulating data suggest that modification of TKT by the negatively charged acyls removed by sirtuin 5, may result in the observed TKT isoforms affecting the enzyme charge and function. The varied responses to the knockout observed in different cells, manifest dependence of the responses on specific homeostatic networks. However, the cell-specific regulation and metabolic impact of the posttranslational modifications of TKT have been characterized only in the artificially created sirtuin 5 knockouts. Therefore, the question on the naturally occurring levels of the TKT acylations and their regulatory potential in the absence of genetic manipulations arises. In this regard, the goal of our study is to characterize the naturally occurring TKT modifications and their role in cellular homeostatic responses which are induced by metabolic challenges instead of genetic manipulations. In view of specific significance of glucose metabolism in the brain and the role of TKT isoenzyme in neurodevelopment [8,9], we focus this study on TKT from the brain cortex tissue. As metabolic challenges, we use the two models of a medically important condition, such as deficient functions of the ThDP-dependent enzymes, central for glucose metabolism. Oxythiamine (OT) is a classic inhibitor of these functions in vivo, as in living systems it is converted into oxy-ThDP, blocking the enzymatic active sites with high affinity [10]. It is also a naturally occurring “damaged” metabolite arising upon the thiamine oxidation under oxidative stress conditions in vivo, such as chronic kidney disease or after kidney transplantation [11-13]. Another known thiamine antagonist, amprolium, is a coccidiostatic [14,15], which blocks intracellular transport of thiamine through ThTR-1 and OCT transporters [10]. Inhibition of the thiamine transport is also known for the antidiabetic drug metformin, blocking cellular thiamine transporters OCT1 and OCT2 better than amprolium, and also inhibiting ThTR-2 [13,16]. As a result, we use these different types of altered thiamine metabolism in rats to assess the functional significance of posttranslational modifications of the rat brain TKT in response to (i) the inhibition of intracellular thiamine transport by a combination of metformin and amprolium (M+A) and (ii) the inhibition of the ThDP-dependent enzymes upon administration of OT. Mass-spectrometry (MS) quantifications of the TKT acylated peptides in the rat brain homogenates show both specific and common features of the alterations in the brain TKT acylations by different inhibitors of thiamine-dependent metabolism.

2. Results

2.1. Effect of Inhibitors of Thiamine-Dependent Metabolism on TKT Acylations in the Rat Brain

Three acylated peptides of TKT detected by MS in the rat brain homogenates, reveal malonylation of K499 residue and acetylations of K102 and K6 residues in the brain TKT (Supplementary Table S1). To quantify relative abundance of these peptides upon the employed metabolic challenges, their levels are normalized to the same (K102- and K499- containing peptides) or independent (K6-containing peptide) non-acylated TKT peptides as described in “Materials and Methods”.

Chronic administration of the in vivo inhibitor of the ThDP-dependent enzymes OT for 30 days causes a 2-fold increase ($p < 0.01$) in the malonylation of TKT K499 residue in the rat cerebral cortex

(Figure 1). Concomitantly, the level of sirtuin 5 is decreased 1.7-fold ($p = 0.01$) by OT (Fig. 1). Since sirtuin 5 is a deacylase specific for negatively charged acyl groups, such as the malonyl group, the observed decrease in sirtuin 5 level agrees well with simultaneous accumulation of TKT malonylation (Figure 1). No effect of OT is observed on the levels of the TKT acetylations at either K6 or K102 residues (Figure 1).

Chronic administration of the thiamine transporters inhibitors M+A for 30 days had no statistically significant effects on the brain levels of TKT acylations or sirtuin 5 expression (Figure 1).




Figure 1. The effects of oxythiamine (OT, orange bars) or metformin and amprolium (M+A, green bars) on the levels of TKT acylations and sirtuin 5 protein in the rat cerebral cortex. The studied animal groups are shown on the X axes. The analyzed parameters are indicated on the Y axes. Comparison of the experimental and control groups is done using Mann-Whitney U-test. p-Values of the significant ($p \leq 0.05$) differences are indicated on the graphs. Crosses denote excluded outliers determined by the ROUT test as described in “Materials and Methods”. Each data point corresponds to an animal. The number of animals in the groups is indicated in the X axes legends.

2.2. Positions of the Brain TKT Acylation Sites in the Resolved Structures of Mammalian TKT

In order to assess potential functional significance of the detected posttranslational modifications of TKT, positions of the acylated residues in the TKT dimer are determined using the structures of mammalian TKT with PDB identifiers 3OOY and 4KXX [17]. The structure 3OOY shows the TKT dimer with bound ThDP. In the structure 4KXX, the TKT N-terminal peptide and the substrate analogue hexahydroxyheptyl dihydrogen phosphate are bound in the active site.

As seen from Figure 2, all the three residues undergoing acylations, namely K6, K102 and K499, are not located in the active site, neither directly participate in the ThDP binding. Rather, the residues belong to the surface of the TKT dimer, although K102 is less exposed to the solvent than K6 or K499.

The TKT N-terminal K6 residue undergoing acetylation is localized within the active-site-comprising N-terminal domain of TKT (Figures 2A, 2B). In the resolved structure 4KXX, the deacetylated positively charged K6 residue forms a salt bridge with the E222 residue, as shown in Figure 2. In another structure of TKT (3OOY), where N-terminus is not resolved, E222 interacts with K16, localized in the first N-terminal alpha-helix of TKT (Figure 2B). Since lysine acetylation removes the positive charge of the lysine residues, the acetylation of K6 should disable its electrostatic

interaction with E222. This may favor the conformation of TKT, where E222 interacts with K16, as in 3OOY.

As seen from Figure 2C, K102^A (subunit A) is also distant from the active site: The closest active site residue R474^B (subunit B) which is involved in substrate binding, is 13.4 Å away from K102^A. However, K102^A is at the entrance to the active site. Acetylation of K102 in TKT may therefore affect electrostatic interactions of the TKT substrates/products entering/exiting the active site. While in both TKT structures (3OOY and 4KXX) the K102^A residue is within the H-bond distance to the oxygen atom of A32^A of the same subunit, it is also 5.5 Å from the E600^B residue of the other subunit. Thus, acetylation of K102^A may also affect the subunit interactions.

The TKT residue K499 is located in a small loop comprising four charged residues – K497, K499, D501, and R530 (Figure 2D). While N ϵ of R530 guanidino group forms an electrostatic interaction with D501, the amino group of deacylated K499 is positioned appropriately for sharing the proton with NH₂ of R530 guanidino group. The K499—malonylation within this loop would create a tetrad of residues forming two salt bridges instead of the positively charged cluster on the TKT surface.




Figure 2. The acylation sites of TKT in the rat cerebral cortex. IDs of the used PDB structures are indicated above each of the four panels. TKT is represented as a cartoon model with different subunits shown in the light and dark shades of gray. The studied lysine residues undergoing acylations, are shown in magenta; the substrate analogue hexahydroxyheptyl dihydrogen phosphate (Hep7P) and ThDP are shown in yellow and green, respectively. Other residues or ligands are shown in gray. Standard color code is used for ions and non-carbon atoms. Brown dashed lines show the H-bonds discussed in the text. (A) – Overall structure of TKT dimer. (B) – The K6 residue of the N-terminal domain of TKT. (C) – The K102 residue of the N-terminal domain of TKT in the vicinity to the active site. The superscripts of the indicated residues denote their belonging to one of the subunits (A or B) in the TKT dimer. (D) – The K499 residue in the central domain of TKT.

2.3. Correlation Analysis of the Interplay between the Levels of TKT Expression, Activity, Acylations and Sirtuin 5

As shown earlier, adaptations to metabolic perturbations involve changes in the metabolic network, which are manifested in correlations between the parameters involved with addressing the perturbations [18-20]. In our study, we assess the role of the varied levels of TKT expression, activity, acylations and sirtuin 5 in the metabolic perturbations induced by OT or M+A. The correlations between these parameters responding to the experimental perturbations in the thiamine-dependent processes are compared to each other (Table 1A) and to the correlations inherent in the control state (Table 1B).

Several relationships between the studied parameters are inherent in the control and perturbed states, manifesting their basic significance. First of all, this is demonstrated by the expectedly strong positive correlations between the endogenous holoenzyme of TKT (assessed by the TKT activity without added ThDP) and total level of TKT (assessed by the TKT activity with added ThDP), observed in all the states (Table 1). Besides, in all the states, the acetylation of K6 and expression of TKT positively correlate

Table 1. Correlations between the levels of TKT and sirtuin 5 proteins, TKT acylations and activity.

Every cell contains a Spearman correlation coefficient (above) and its p-value (below). The cells presenting the correlations with significant ($p < 0.05$) p-values are marked with bold font and colored in red for the positive correlation coefficients or blue for the negative ones. The cells presenting the correlation trends ($0.05 < p < 0.1$) are marked with italic font and a lower color intensity. **A.** The correlations of the indicated parameters determined for the pooled animals studied in the experiments with metformin and amprolium (M+A, top right, $n = 16-23$) or oxythiamine (OT, bottom left, $n = 21-26$). **B.** The correlations of parameters determined in the control animals ($n=15-22$) with the expression of sirtuin 5, although the TKT-sirtuin 5 correlation becomes more significant in the perturbed states (Table 1), presumably an indicator of its adaptive role.

A. Perturbations in thiamine metabolism

OT \ M+A	Mal-K499	Ac-K6	Ac-K102	TKT-expr	Act -ThDP	Act +ThDP	Sirt5
Mal-K499	1.00	-0.14	-0.15	0.20	-0.07	-0.22	-0.19
	0.00	0.66	0.62	0.51	0.80	0.43	0.53
Ac-K6	-0.22	1.00	-0.08	0.22	-0.35	-0.38	0.76
	0.31	0.00	0.74	0.35	<i>0.12</i>	<i>0.09</i>	0.00
Ac-K102	0.03	0.13	1.00	0.26	-0.45	-0.41	-0.11
	0.88	0.54	0.00	0.25	0.04	<i>0.07</i>	0.65
TKT-expr	-0.08	-0.04	0.12	1.00	-0.45	-0.47	0.59
	0.73	0.84	0.55	0.00	0.04	0.03	0.01
Act -ThDP	-0.52	-0.47	-0.10	0.15	1.00	0.95	-0.26
	0.01	0.02	0.62	0.47	0.00	0.00	0.26
Act +ThDP	-0.40	-0.50	-0.20	-0.08	0.97	1.00	-0.30
	<i>0.07</i>	0.01	0.35	0.72	0.00	0.00	0.19
Sirt5	-0.16	0.60	-0.18	0.51	-0.21	-0.30	1.00
	0.47	0.00	0.38	0.01	0.31	0.15	0.00

B. Control state

	Mal-K499	Ac-K6	Ac-K102	TKT-expr	Act -ThDP	Act +ThDP	Sirt5
Mal-K499	1.00	-0.12	-0.26	0.32	-0.31	-0.36	0.18
	0.00	0.68	0.34	0.24	0.23	0.19	0.52
Ac-K6		1.00	-0.36	-0.20	-0.16	-0.25	0.61
		0.00	0.10	0.37	0.49	0.28	0.00
Ac-K102			1.00	0.04	0.07	0.02	-0.52
			0.00	0.88	0.76	0.94	0.01
TKT-expr				1.00	0.07	-0.10	0.40
				0.00	0.76	0.67	0.06
Act -ThDP					1.00	0.93	-0.10
					0.00	0.00	0.67
Act +ThDP						1.00	-0.14
						0.00	0.53
Sirt5							1.00
							0.00

Paradoxically, TKT protein expression does not correlate positively with the TKT activity in either the control or perturbed states. Moreover, in the M+A model, the TKT expression negatively correlates with TKT activity (Table 1). This finding stresses the role of posttranslational regulation of TKT activity.

Indeed, the correlations of the TKT acetylation undergo significant and perturbation-specific changes, compared to the control state. A strong negative correlation between the acetylation level of K102 and sirtuin 5 protein and a low negative correlation between the acetylations of K102 and K6 are observed in the control state (Table 1B), but disappear in the two perturbed states (Table 1A). In the M+A experiment, the loss of the negative relationships of the acetylated TKT K102 with sirtuin 5 or acetylated K6, inherent in the control animals (Table 1B), are accompanied by appearance of the negative correlations of the acetylation levels of K102 and, to a lesser extent, of K6, with TKT activity (Table 1A). In the OT series, significant negative correlations of the TKT activity with the levels of K6 acetylation and K499 malonylation become evident (Table 1A) under the lost relationships between the TKT acetylations and sirtuin 5 (Table 1B). As a result, the metabolic perturbations change the interplay between the TKT acylations and sirtuin 5, that is associated with a negative impact of the acylations on the TKT activity.

Altogether, the correlation analysis reveals a basic relationship between the protein expression of TKT and sirtuin 5, that is involved in the control of the TKT activity by acylation of its lysine residues. While the increased correlation between the protein expression of TKT and sirtuin 5 under the metabolic perturbations, especially that by OT, points to a heightened relationship between the two proteins under the perturbation of the thiamine-dependent metabolism, the perturbations-induced disbalance in the acylation system becomes evident from the negative impact of the TKT acylations on the enzyme activity (Table 1). Although the different acylations of TKT are highly interdependent, the inhibitors of the thiamine intracellular transport (M+A) or of the ThDP-dependent enzymatic functions (OT) induce the perturbation-specific shifts in the regulation of TKT function by site-specific acetylation and malonylation.

3. Discussion

This work reveals for the first time that perturbations in the thiamine-dependent metabolism upon administration to rats of the inhibitors of intracellular thiamine transporters (M+A) or of ThDP-dependent enzymes (OT) are manifested in the posttranslational acylations of the brain TKT. The regulation of TKT by acylation of its lysine residues agrees with our observation of a correlated expression of TKT and sirtuin 5, with the correlation heightened in the metabolically challenged animals. Moreover, different types, i.e. malonylation and acetylation, and sites, i.e. K6, K102 and K499, of the brain TKT acylation specifically respond to the different inhibitors of the thiamine-dependent processes (M+A or OT). Only when the function of the ThDP-dependent enzymes is strongly perturbed by OT administration, an increase in TKT malonylation is observed, accompanied by decreased expression of the demalonylase sirtuin 5 (Figure 1). The TKT acetylation undergoes subtle changes revealed by correlation analysis, in both models. The inhibitors-induced changes point to induction of negative correlations between the TKT activity and the TKT acetylation at either K6 (the action of OT), or K102 (the action of M+A) residues.

3.1. The Brain TKT Regulation by Malonylation

Our correlation analysis indicates that the level of the brain TKT K499 malonylation, occurring in the OT-treated animals, increases along with decreasing activity of TKT (Table 1A). In good agreement with this result on the negative relationship between the TKT activity and malonylation levels, cellular incubation with malonyl-CoA inactivates endogenous TKT inside the colorectal cancer cells [6]. K499 belongs to the TKT central domain which participates in the active site formation [1,21]. However, given the distant position of K499 from the active site (Figure 2), the negative correlation between K499 malonylation and TKT activity (Table 1A) suggests an indirect involvement of K499 in the TKT regulation. Probably, K499 malonylation is a marker of other events associated with a lower TKT activity. For instance, malonylation of TKT may also occur at other lysine residues, within or near the active site, but these peptides are not detectable in our assay. Using the sirtuin 5 silencing and overexpression of TKT constructs [6], malonylation of TKT K281 has been suggested to cause a decrease in the TKT activity. Unfortunately, the relevant TKT malonylation intensities in this study lack quantification and statistical significance, that interferes with conclusive comparison of the TKT activity and K281 malonylation levels, done by the authors. Localization of K281 far away from the active site in the structures of human TKT (PDB 3OOY and 4KXX) does not support its functional role in the TKT substrate binding or catalysis. However, taking into account that both these malonylated sites in TKT, i.e. K281 and K499, occur within the patches having up to three positively charged residues, the role of the TKT malonylation in controlling electrostatic interactions with other proteins or nucleic acids, that may well regulate the enzyme activity, may be suggested. Indeed, yeast TKT forms a stable complex with RNA [22,23]. TKT is also known to form a binary complex with glyceraldehyde-3-phosphate dehydrogenase [24] or the ternary complex between transketolase, transaldolase, and glyceraldehyde-3-phosphate dehydrogenase [25]. Such protein complexes may be physiologically important for glucose distribution between different pathways, involving the TKT activity adjustment according to metabolic demands. Interestingly, in the liver of mice with sirtuin 5 knockout, increased malonylation of glyceraldehyde-3-phosphate dehydrogenase decreases glycolytic flux [7]. Based on this finding, the authors suggest the glucose redirection from glycolysis to PPP or glycogen synthesis. In contrast, in the colorectal cancer cells, the sirtuin 5 knockout inhibits the PPP-dependent production of ribose-5-phosphate in the non-oxidative branch along with the TKT malonylation [6]. Mutual regulation of the protein-protein interactions and malonylation in the complex between TKT and glyceraldehyde-3-phosphate dehydrogenase may thus be a key to distribution of glucose between different pathways in a cell-specific manner. The interaction of mammalian TKT with glucose-regulated protein 78 (GRP78, also known as BIP) in colorectal cancer cells [26] provides further support for the role of the malonylation-regulated protein-protein interactions of TKT in the control of glucose fluxes.

3.2. The Brain TKT Regulation by Acetylation

The TKT K6 and K102 residues undergoing acetylation, belong to the N-terminal domain whose residues form the active site. Although the acetylated K6 and K102 residues are far away from the active site (Figure 2), their acetylation may change electrostatic interactions within the N-terminal domain and close to the subunits interface. The acetylation-regulated formation of the alternative salt bridges between E222 and either K6 or K16, may affect the conformational state of the TKT N-terminus. In its turn, the conformational shifts within the active-site-forming N-terminal domain may affect the TKT activity through further changing the conformation of the active site. Besides, structurally disordered protein parts, such as disordered N-terminus of TKT, often participate in protein-protein interactions, that may also affect the enzyme activity. A less exposed to the solvent, K102 residue at the entrance to the active site may be involved in the acetylation-dependent control of the substrates access to the active site or the products exit. The residue acetylation may also affect interactions between the TKT subunits which are significant for the enzyme catalysis [27,28]. All these factors may underlie the negative correlation between the K102 acetylation and TKT activity (Table 1A, M+A).

Recent data on regulation of the TKT proteolytic degradation suggests the role of acetylation in the enzyme stabilization. In HeLa and RPMI8226 cells, acetylation of TKT K6 residue results in a slower protein degradation, compared to the non-acetylated TKT [29]. The TKT K102 and K499 residues are known to be ubiquitinated [29]. In view of the ubiquitination-directed proteolysis, the acetylation of the TKT residues, competitive to their ubiquitination, may prevent such proteolysis. However, the negative correlations of the TKT activity and acetylation do not testify to the decreased proteolysis of the active (in standard assay) TKT. Yet the existence of the TKT pool which is not catalytically active in the assayed TKT reaction, is supported by no correlation between the TKT expression and activity, even when the total activity is determined in the presence of ThDP (Table 1). Moreover, administration to animals of the thiamine transporters inhibitors induces the negative correlation between the TKT expression and activity (Table 1A). Altogether, the data suggest that the TKT acetylation may be linked to some “moonlighting” [30] function of TKT, inactive in its traditional catalytic reaction. Indeed, TKT from yeast is inactive when complexed with RNA, although the biological significance of this complex is unknown [23]. Transketolase of *Escherichia coli* is a transcription factor [31]. The TKT binding to nucleic acids, usually employing electrostatic interactions, is especially interesting in regards of the protein acetylation. Other moonlighting functions of TKT are linked to the enzyme secretion. Secretion of TKT by *Entamoeba histolytica* discriminates between the pathogenic and non-pathogenic strains [32]. TKT is also known to be localized on the cellular surface of *Mycoplasma pneumoniae*, where its interaction with the host plasminogen determines a success of the long-term colonization of the human respiratory system [33]. In mammals, TKT is known to translocate to nucleus [8,34]. In ischemic heart failure, nuclear TKT binds to poly(ADP-ribose) polymerase 1, facilitating the polymerase cleavage, and activates apoptosis-inducible factor [34]. One cannot therefore exclude that TKT inactive in its traditional reaction, may be expressed for some moonlighting functions in the brain. Contribution of this inactive TKT to the total TKT protein, quantified by our MS analysis, is suggested by the absence or even negative correlation between the brain TKT expression and activity (Table 1).

4. Materials and Methods

4.1. Reagents

When not specified otherwise, chemicals were obtained from Merck (Dia-m, Moscow, Russia). Metformin (Merck, #D150959, Dia-m, Moscow, Russia), amprolium (Merck, # A0542, Dia-m, Moscow, Russia), oxythiamine (Merck, # O4000, Dia-m, Moscow, Russia) were dissolved at the day of injections and pH was adjusted to neutral with NaOH, if necessary. The barium salt of phosphopentose mixture containing xylulose 5-phosphate and ribose 5-phosphate was prepared using an earlier described method [35]. The barium salt was converted to the potassium salt before use with Dowex 50W-X8 in H⁺-form (Merck, #1.05221, Dia-m, Moscow, Russia). α -Glycerophosphate

dehydrogenase-triosephosphate isomerase mixture was from Merck (#G1881, Dia-M, Moscow, Russia). Deionized MQ-grade water was used for solution preparations.

4.2. Animal Experiments

All animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals published by the European Union Directives 86/609/EEC and 2010/63/EU, and were approved by Bioethics Committee of Lomonosov Moscow State University (protocol 139-a-2 from 19 May 2022).

Fifty-one Wistar (RRID: RGD_13508588) male rats (approx. 5–6 weeks and 158.7±11.0 g in the beginning of the experiment, 9–10 weeks and 304.7±25.9 g in the end of the experiment) were used in the two independent animal series. Each series contained an experimental group and a control group. Oxythiamine was administered to rats (n=16, one died) as a single i.p. injection with a corresponding control group (n=11) receiving equal volumes of physiological solution (0.9% sodium chloride). A combination of metformin and amprolium was administered to rats (n=12, one died) as two separate injections and the control group (n=12) also received the two injections of physiological solution. In the MS experiment up to seven samples were lost due to technical reasons in the series with metformin and amprolium, therefore the number of animals for each of the MS-detected parameters was decreased as indicated in the figures.


The injections were made in the morning ($ZT 2 \pm 1$) for 30 days long without breaks. Oxythiamine was administered at a dose of 1.5 mg per kg. Metformin was administered at a dose of 150 mg per kg and amprolium – at a dose of 40 mg per kg. Doses were selected based on literature data and preliminary experiments to achieve significant effects with minimal lethality [36–39]. Doses between species were recalculated using formula recommended by FDA [40]. Two rats - one from the group with the combination of metformin and amprolium and one from the oxythiamine group – died before the end of the study on days 9th and 16th, respectively. 24 h after the last injections the animals were killed by decapitation. The brains were excised and transferred on ice, where the cortices were separated to be frozen in liquid nitrogen 60–90 s after decapitation. The cortices were stored at -70°C .

4.3. Homogenization of Rat Brain Tissue

The brain cortex tissue (0.5 g) was homogenized for 2 min in 1.25 mL of the homogenization buffer (50 mM MOPS, pH = 7.0, containing 2.7 mM EDTA, 20% glycerol and protease inhibitors: 0.2 mM AEBSF, 0.16 μM aprotinin, 3.33 μM bestatin, 3 μM E-64, 2 μM leupeptin, and 1.4 μM pepstatin A), using a ULTRA-TURRAX® T-10 Basic disperser (IKA, Staufen, Germany) at the speed parameter “3” as described before [19]. The homogenates were sonicated by Bioruptor® (Diagenode, Liege, Belgium) for 7 cycles of 30 s sonication and 30 s pause at the sonicator low intensity.

4.4. TKT Activity Assay

The catalytic activity of TKT in the cerebral cortex homogenates was measured spectrophotometrically using CLARIOstar Plus microplate reader (BMG Labtech, Ortenberg, Germany) in the Reaction:



The rate of NADH oxidation in the coupled system shown above was measured using an earlier described method [41]. TKT was measured in an aliquot of each homogenate, preincubated with an equal volume of the 50 mM glycylglycine buffer with 3 mM CaCl_2 , pH 7.6, on ice for at least 30 min before measurement. The reaction mixture contained 50 mM glycylglycine, 2.5 mM MgCl_2 , 0.25 mM NADH, 3 U/ml of triosephosphate isomerase and glyceraldehydephosphate dehydrogenase, 3 mg/ml potassium salt of the phosphopentose mixture, pH 7.6, and 0.2 mM ThDP (to assay total level of active TKT in the homogenates) or no ThDP (to assay endogenous level of holoTKT in the homogenates). A 30 min preincubation of the samples in the reaction mixture without phosphopentose solution was used. The reaction was initiated by the addition of phosphopentoses. The blank was assayed omitting phosphopentoses.

4.5. Analysis of Peptides by LC-MS/MS

The polyacrylamide gels were subjected to in-gel digestion and Nano-LC-MS/MS analysis as described earlier [40]. The spectra acquisition consisted of an orbitrap full MS scan (FTMS; resolution 60,000; m/z range 400–2000) followed by up to 15 LTQ MS/MS experiments (Linear Trap; minimum signal threshold: 500; dynamic exclusion time setting: 30 s; singly charged ions were excluded from selection, normalized collision energy: 35%; activation time: 10 ms). Raw data processing, protein identification and phosphorylation assignment of the high resolution orbitrap data were performed by PEAKS Studio Xpro (Bioinformatics Solutions, Waterloo, ON, USA). False discovery rate was set to <1%.

4.6. Quantification of the TKT Acylations and Sirtuin 5 Protein Level

Relative MS-based quantification of peptides of TKT, Sirtuin 5, beta-actin, and beta-tubulin, presented in the Supplementary Table S1, was performed using the Skyline platform [42] as described previously [40,43]. The relative protein expression levels of TKT and Sirtuin 5 in each sample were calculated using the sum of unique peptides, corresponding to a particular rat protein (Supplementary Table S1). Within each sample corresponding to a single animal, the relative expression of the detected proteins was normalized to the sum of relative expressions of beta-actin and beta-tubulin (Supplementary Table S1). The relative levels of TKT K102 acetylation and K499

malonylation were determined as the ratio of the same peptides, comprising the acylated and non-acylated residue. When the non-modified peptide was not identified, as in case of the K6-containing peptide, the normalization was done to the sum of four normalizing peptides of TKT (Supplementary Figure S1) as described previously [40,43]. All the used peptides are listed in the Supplementary Table S1 together with the corresponding mass and charge parameters.

4.7. Structural Visualization

PyMOL v2.5 (PyMOL Molecular Graphics System, Schrödinger, LLC) is used for visualization of TKT. Variable conformational states of mammalian TKT were assessed employing the PDB-deposited TKT structures 3OOY (with ThDP) and 4KXX (with ThDP and hexahydroxyheptyl dihydrogen phosphate in the substrate site). Superposition of the structures was done with the help of multiple structural alignment by PyMOL.

4.8. Statistics

Statistical analysis was performed using GraphPad Prism, version 8.0 (GraphPad Software Inc., La Jolla, CA, USA). Normal distribution was tested using D'Agostino and Pearson omnibus normality test ($p < 0.05$). Since not all the parameters were distributed normally, Spearman correlations were used for the correlation analysis. Differences between two groups are analyzed using the Mann–Whitney U-test. The ROUT test for outliers [44] is applied using the default parameter of Q coefficient equal to 1%.

5. Conclusions

Posttranslational modifications of TKT by acylations are involved in the brain response to perturbed thiamine-dependent metabolism. Negative correlations of the TKT activity with acetylation of K6 and K102 residues and malonylation of K499 residue are observed. The residues are located on the enzyme surface distant from active site. The acylations may affect the TKT function through changed electrostatic interactions, causing conformational shifts and/or regulating the TKT interactions with proteins or nucleic acids. Malonylation of K499 in TKT is significantly changed along with decreased sirtuin 5 expression upon the oxythiamine-perturbed function of ThDP-dependent enzymes. No positive correlation between the TKT protein expression quantified in the brain homogenates by MS, and the TKT activity in the transketolase reaction in the presence of ThDP, suggests significant portion of the brain TKT to be in the catalytically inactive state.

Supplementary Materials: The following supporting information can be downloaded at: www.mdpi.com/xxx/s1, Table S1.

Author Contributions: Conceptualization, V.I.B.; Methodology, A.V.G. and M.V.M (Animal Experiments), T.K. (Mass-Spectrometry), Validation, Formal Analysis, Investigation, Data Curation, Visualization, V.I.B. and V.A.A.; Writing—Original Draft Preparation, V.A.A. and V.I.B.; Writing—review and editing, V.I.B.; Supervision, V.I.B.; Project Administration, V.I.B. All authors have read and agreed to the published version of the manuscript.

Acknowledgement: The authors greatly acknowledge valuable discussions with Dr. Solovieva regarding the determination of transketolase activity and her enzyme assays.

Funding: This research was supported by the state financing of the scientific theme AAAA-A19-119042590056-2

Institutional Review Board Statement: The animal study protocol was approved by Bioethics Committee of Lomonosov Moscow State University (protocol 139-a-2 from 19 May 2022).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in this article and supplementary materials.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Abbreviations

TKT – transketolase,
ThDP – thiamine diphosphate,
PPP – pentose phosphate pathway,
OT – oxythiamine,
M+A – metformin and amprolium,
MS – mass-spectrometry.

References

1. Lindqvist, Y.; Schneider, G.; Ermler, U.; Sundstrom, M. Three-dimensional structure of transketolase, a thiamine diphosphate dependent enzyme, at 2.5 Å resolution. *The EMBO journal* **1992**, *11*, 2373-2379, doi:10.1002/j.1460-2075.1992.tb05301.x.
2. Blass, J.P.; Gibson, G.E. Abnormality of a thiamine-requiring enzyme in patients with Wernicke-Korsakoff syndrome. *The New England journal of medicine* **1977**, *297*, 1367-1370, doi:10.1056/NEJM197712222972503.
3. Mukherjee, A.B.; Svoronos, S.; Ghazanfari, A.; Martin, P.R.; Fisher, A.; Roecklein, B.; Rodbard, D.; Staton, R.; Behar, D.; Berg, C.J., et al. Transketolase abnormality in cultured fibroblasts from familial chronic alcoholic men and their male offspring. *The Journal of clinical investigation* **1987**, *79*, 1039-1043, doi:10.1172/JCI112916.
4. Martin, P.R.; McCool, B.A.; Singleton, C.K. Molecular genetics of transketolase in the pathogenesis of the Wernicke-Korsakoff syndrome. *Metabolic brain disease* **1995**, *10*, 45-55, doi:10.1007/BF01991782.
5. Ou, T.; Yang, W.; Li, W.; Lu, Y.; Dong, Z.; Zhu, H.; Sun, X.; Dong, Z.; Weng, X.; Chang, S., et al. SIRT5 deficiency enhances the proliferative and therapeutic capacities of adipose-derived mesenchymal stem cells via metabolic switching. *Clin Transl Med* **2020**, *10*, e172, doi:10.1002/ctm2.172.
6. Wang, H.L.; Chen, Y.; Wang, Y.Q.; Tao, E.W.; Tan, J.; Liu, Q.Q.; Li, C.M.; Tong, X.M.; Gao, Q.Y.; Hong, J., et al. Sirtuin5 protects colorectal cancer from DNA damage by keeping nucleotide availability. *Nature communications* **2022**, *13*, 6121, doi:10.1038/s41467-022-33903-8.
7. Nishida, Y.; Rardin, M.J.; Carrico, C.; He, W.; Sahu, A.K.; Gut, P.; Najjar, R.; Fitch, M.; Hellerstein, M.; Gibson, B.W., et al. SIRT5 Regulates both Cytosolic and Mitochondrial Protein Malonylation with Glycolysis as a Major Target. *Molecular cell* **2015**, *59*, 321-332, doi:10.1016/j.molcel.2015.05.022.
8. Pandya, N.J.; Meier, S.; Tyanova, S.; Terrigno, M.; Wang, C.; Punt, A.M.; Mientjes, E.J.; Vautheny, A.; Distel, B.; Kremer, T., et al. A cross-species spatiotemporal proteomic analysis identifies UBE3A-dependent signaling pathways and targets. *Mol Psychiatry* **2022**, *27*, 2590-2601, doi:10.1038/s41380-022-01484-z.
9. Pinson, A.; Xing, L.; Namba, T.; Kalebic, N.; Peters, J.; Oegema, C.E.; Traikov, S.; Reppe, K.; Riesenberger, S.; Maricic, T., et al. Human TKTL1 implies greater neurogenesis in frontal neocortex of modern humans than Neanderthals. *Science* **2022**, *377*, eabl6422, doi:10.1126/science.abl6422.
10. Bunik, V.I.; Tylicki, A.; Lukashev, N.V. Thiamin diphosphate-dependent enzymes: from enzymology to metabolic regulation, drug design and disease models. *The FEBS journal* **2013**, *280*, 6412-6442, doi:10.1111/febs.12512.
11. Zhang, F.; Masania, J.; Anwar, A.; Xue, M.; Zehnder, D.; Kanji, H.; Rabbani, N.; Thornalley, P.J. The uremic toxin oxythiamine causes functional thiamine deficiency in end-stage renal disease by inhibiting transketolase activity. *Kidney international* **2016**, *90*, 396-403, doi:10.1016/j.kint.2016.03.010.
12. Golan, O.; Dyer, R.; Sinclair, G.; Blydt-Hansen, T. Investigating oxythiamine levels in children undergoing kidney transplantation and the risk of immediate post-operative metabolic and hemodynamic decompensation. *Pediatr Nephrol* **2021**, *36*, 987-993, doi:10.1007/s00467-020-04797-9.
13. Aleshin, V.A.; Mkrtchyan, G.V.; Bunik, V.I. Mechanisms of Non-coenzyme Action of Thiamine: Protein Targets and Medical Significance. *Biochemistry. Biokhimiia* **2019**, *84*, 829-850, doi:10.1134/S0006297919080017.
14. Rogers, E.F. General discussion of antithiamin compounds and thiamin antagonists. *Annals of the New York Academy of Sciences* **1982**, *378*, 157-160, doi:10.1111/j.1749-6632.1982.tb31194.x.
15. Al-Otaibi, T.; Hawsah, M.A.; Alojyri, G.; Mares, M.M.; Aljawdah, H.M.A.; Maodaa, S.N.; Al-Shaebi, E.M.; Dkhil, M.A.; Thagfan, F.A.; Al-Quraishy, S., et al. In vivo anticoccidial, antioxidant, and anti-inflammatory

- activities of avocado fruit, *Persea americana* (Lauraceae), against *Eimeria papillata* infection. *Parasitol Int* **2023**, *95*, 102741, doi:10.1016/j.parint.2023.102741.
16. Bunik, V.I.; Aleshin, V.A. Analysis of the Protein Binding Sites for Thiamin and Its Derivatives to Elucidate the Molecular Mechanisms of the Noncoenzyme Action of Thiamin (Vitamin B1). *Studies in Natural Products Chemistry* **2017**, *53*, 375-429, doi:10.1016/b978-0-444-63930-1.00011-9.
 17. Ludtke, S.; Neumann, P.; Erixon, K.M.; Leeper, F.; Kluger, R.; Ficner, R.; Tittmann, K. Sub-angstrom-resolution crystallography reveals physical distortions that enhance reactivity of a covalent enzymatic intermediate. *Nat Chem* **2013**, *5*, 762-767, doi:10.1038/nchem.1728.
 18. Zavileyskiy, L.G.; Aleshin, V.A.; Kaehne, T.; Karlina, I.S.; Artiukhov, A.V.; Maslova, M.V.; Graf, A.V.; Bunik, V.I. The Brain Protein Acylation System Responds to Seizures in the Rat Model of PTZ-Induced Epilepsy. *International journal of molecular sciences* **2022**, *23*, doi:10.3390/ijms232012302.
 19. Artiukhov, A.V.; Graf, A.V.; Kazantsev, A.V.; Boyko, A.I.; Aleshin, V.A.; Ksenofontov, A.L.; Bunik, V.I. Increasing Inhibition of the Rat Brain 2-Oxoglutarate Dehydrogenase Decreases Glutathione Redox State, Elevating Anxiety and Perturbing Stress Adaptation. *Pharmaceuticals (Basel)* **2022**, *15*, doi:10.3390/ph15020182.
 20. Aleshin, V.A.; Zhou, X.; Krishnan, S.; Karlsson, A.; Bunik, V.I. Interplay Between Thiamine and p53/p21 Axes Affects Antiproliferative Action of Cisplatin in Lung Adenocarcinoma Cells by Changing Metabolism of 2-Oxoglutarate/Glutamate. *Frontiers in Genetics* **2021**, *12*, doi:10.3389/fgene.2021.658446.
 21. Nikkola, M.; Lindqvist, Y.; Schneider, G. Refined structure of transketolase from *Saccharomyces cerevisiae* at 2.0 Å resolution. *Journal of molecular biology* **1994**, *238*, 387-404, doi:10.1006/jmbi.1994.1299.
 22. Solovjeva, O.N. Isolation and Properties of Noncovalent Complex of Transketolase with RNA. *Biochemistry (Moscow)* **2002**, *67*, 667-671, doi:10.1023/a:1016198321838.
 23. Tikhomirova, N.K.; Merchan, A.Y.; Kochetov, G.A. A new form of baker's yeast transketolase. An enzyme-RNA complex. *FEBS letters* **1990**, *274*, 27-29, doi:10.1016/0014-5793(90)81321-e.
 24. Kochetov, G.A.; Nikitushkina, L.I.; Chernov, N.N. A complex of functionally-bound enzymes: transketolase and glyceraldehydephosphate dehydrogenase. *Biochemical and biophysical research communications* **1970**, *40*, 873-879, doi:10.1016/0006-291x(70)90984-8.
 25. Wood, T.; Muzariri, C.C.; Malaba, L. Complex formation between transketolase, transaldolase, and glyceraldehyde phosphate dehydrogenase. *International Journal of Biochemistry* **1985**, *17*, 1109-1115, doi:10.1016/0020-711x(85)90044-8.
 26. Li, M.; Zhao, X.; Yong, H.; Xu, J.; Qu, P.; Qiao, S.; Hou, P.; Li, Z.; Chu, S.; Zheng, J., et al. Transketolase promotes colorectal cancer metastasis through regulating AKT phosphorylation. *Cell Death Dis* **2022**, *13*, 99, doi:10.1038/s41419-022-04575-5.
 27. Sevostyanova, I.; Solovjeva, O.; Selivanov, V.; Kochetov, G. Half-of-the-sites reactivity of transketolase from *Saccharomyces cerevisiae*. *Biochemical and biophysical research communications* **2009**, *379*, 851-854, doi:10.1016/j.bbrc.2008.12.108.
 28. Kovina, M.V.; Kochetov, G.A. Cooperativity and flexibility of active sites in homodimeric transketolase. *FEBS letters* **1998**, *440*, 81-84, doi:10.1016/s0014-5793(98)01423-9.
 29. Zecha, J.; Gabriel, W.; Spallek, R.; Chang, Y.C.; Mergner, J.; Wilhelm, M.; Bassermann, F.; Kuster, B. Linking post-translational modifications and protein turnover by site-resolved protein turnover profiling. *Nature communications* **2022**, *13*, 165, doi:10.1038/s41467-021-27639-0.
 30. Jeffery, C.J. An enzyme in the test tube, and a transcription factor in the cell: Moonlighting proteins and cellular factors that affect their behavior. *Protein science : a publication of the Protein Society* **2019**, *28*, 1233-1238, doi:10.1002/pro.3645.
 31. Domain, F.; Bina, X.R.; Levy, S.B. Transketolase A, an enzyme in central metabolism, derepresses the marRAB multiple antibiotic resistance operon of *Escherichia coli* by interaction with MarR. *Molecular microbiology* **2007**, *66*, 383-394, doi:10.1111/j.1365-2958.2007.05928.x.
 32. Ahn, C.S.; Kim, J.G.; Shin, M.H.; Lee, Y.A.; Kong, Y. Comparison of Secretome Profile of Pathogenic and Non-Pathogenic *Entamoeba histolytica*. *Proteomics* **2018**, *18*, e1700341, doi:10.1002/pmic.201700341.
 33. Grundel, A.; Pfeiffer, M.; Jacobs, E.; Dumke, R. Network of Surface-Displayed Glycolytic Enzymes in *Mycoplasma pneumoniae* and Their Interactions with Human Plasminogen. *Infect Immun* **2015**, *84*, 666-676, doi:10.1128/IAI.01071-15.
 34. Wang, Z.; Qiu, Z.; Hua, S.; Yang, W.; Chen, Y.; Huang, F.; Fan, Y.; Tong, L.; Xu, T.; Tong, X., et al. Nuclear Tkt promotes ischemic heart failure via the cleaved Parp1/Aif axis. *Basic Res Cardiol* **2022**, *117*, 18, doi:10.1007/s00395-022-00925-8.
 35. Gubler, C.J.; Johnson, L.R.; Wittorf, J.H. [22] Yeast transketolase (sedoheptulose-7-phosphate:d-glyceraldehyde-3-phosphate dihydroxyacetone transferase, EC 2.2.1.1) assay of thiamine diphosphate. In *Vitamins and Coenzymes*, 1970; 10.1016/0076-6879(71)18290-0pp. 120-125.

36. Brin, M. Effects of thiamine deficiency and of oxythiamine on rat tissue transketolase. *The Journal of nutrition* **1962**, 78, 179-183, doi:10.1093/jn/78.2.179.
37. Moraes, J.O.; Rodrigues, S.D.C.; Pereira, L.M.; Medeiros, R.C.N.; de Cordova, C.A.S.; de Cordova, F.M. Amprolium exposure alters mice behavior and metabolism in vivo. *Animal Model Exp Med* **2018**, 1, 272-281, doi:10.1002/ame2.12040.
38. Oliveira, W.H.; Nunes, A.K.; Franca, M.E.; Santos, L.A.; Los, D.B.; Rocha, S.W.; Barbosa, K.P.; Rodrigues, G.B.; Peixoto, C.A. Effects of metformin on inflammation and short-term memory in streptozotocin-induced diabetic mice. *Brain research* **2016**, 1644, 149-160, doi:10.1016/j.brainres.2016.05.013.
39. Kalariya, N.M.; Shoeb, M.; Ansari, N.H.; Srivastava, S.K.; Ramana, K.V. Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats. *Investigative ophthalmology & visual science* **2012**, 53, 3431-3440, doi:10.1167/iovs.12-9432.
40. Aleshin, V.A.; Mkrtchyan, G.V.; Kaehne, T.; Graf, A.V.; Maslova, M.V.; Bunik, V.I. Diurnal regulation of the function of the rat brain glutamate dehydrogenase by acetylation and its dependence on thiamine administration. *Journal of neurochemistry* **2020**, 153, 80-102, doi:10.1111/jnc.14951.
41. de la Haba, G.; Leder, I.G.; Racker, E. Crystalline Transketolase from Bakers' Yeast: Isolation and Properties. *Journal of Biological Chemistry* **1955**, 214, 409-426, doi:10.1016/s0021-9258(18)70978-2.
42. MacLean, B.; Tomazela, D.M.; Shulman, N.; Chambers, M.; Finney, G.L.; Frewen, B.; Kern, R.; Tabb, D.L.; Liebler, D.C.; MacCoss, M.J. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. *Bioinformatics* **2010**, 26, 966-968, doi:10.1093/bioinformatics/btq054.
43. Aleshin, V.A.; Artiukhov, A.V.; Kaehne, T.; Graf, A.V.; Bunik, V.I. Daytime Dependence of the Activity of the Rat Brain Pyruvate Dehydrogenase Corresponds to the Mitochondrial Sirtuin 3 Level and Acetylation of Brain Proteins, All Regulated by Thiamine Administration Decreasing Phosphorylation of PDHA Ser293. *International journal of molecular sciences* **2021**, 22, doi:10.3390/ijms22158006.
44. Motulsky, H.J.; Brown, R.E. Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. *BMC bioinformatics* **2006**, 7, 123, doi:10.1186/1471-2105-7-123.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.